바이오시밀러 시장 분석 및 예측(-2035년) : 유형, 제품, 서비스, 기술, 용도, 프로세스, 최종 사용자, 단계

The global Biosimilars Market is projected to grow from $28.1 billion in 2025 to $138.0 billion by 2035, at a compound annual growth rate (CAGR) of 17.3%. The biosimilars market is driven by increasing demand for cost-effective biologic therapies, rising healthcare expenditure, and expanding regulatory support for biosimilar development and adoption. According to the U.S. FDA, more than 70 biosimilar products had been approved in the United States by the end of 2025, expanding patient access to biologic therapies across oncology, immunology, endocrinology, ophthalmology, and other therapeutic areas. Continued biosimilar approvals, streamlined regulatory pathways, and increasing physician, payer, and patient acceptance are supporting broader biosimilar adoption and driving market growth.

The Type segment of the Biosimilars Market includes recombinant non-glycosylated proteins, recombinant glycosylated proteins, recombinant peptides, and others. Among these, recombinant glycosylated proteins represent a significant market share due to their extensive use in complex therapeutic areas, including oncology, autoimmune diseases, and chronic conditions. These biosimilars offer cost-effective alternatives to biologic therapies while maintaining comparable efficacy and safety profiles. Recombinant non-glycosylated proteins, such as insulin and growth hormones, continue to witness steady demand due to their established clinical applications. Recombinant peptides are also gaining traction with increasing adoption in metabolic disorders and hormone-related therapies, supported by advancements in biotechnology and manufacturing processes.

The End User segment of the Biosimilars Market includes hospitals, clinics, research institutes, biopharmaceutical companies, and others. Hospitals represent a major end-user segment due to the increasing adoption of biosimilar therapies for cost-effective treatment of chronic diseases, cancer, and autoimmune disorders. Biopharmaceutical companies are driving market growth through investments in biosimilar development, manufacturing capabilities, and regulatory approvals. Research institutes play a crucial role in advancing biosimilar characterization, clinical studies, and analytical testing. Clinics are also contributing to market expansion through the growing use of biosimilars in outpatient care and long-term disease management. Increasing healthcare cost pressures and improved regulatory support are further accelerating biosimilar adoption globally.

Geographical Overview

North America held the largest share of the global biosimilars market in 2025, driven by increasing adoption of cost-effective biologic alternatives, rising healthcare expenditure, and a favorable regulatory environment supporting biosimilar approvals. The region has witnessed growing acceptance of biosimilars among healthcare providers and patients as healthcare systems seek to reduce treatment costs while maintaining therapeutic efficacy. The presence of leading biopharmaceutical companies, expanding investments in biologics manufacturing, and increasing patent expirations of blockbuster biologic drugs have further accelerated market growth. Additionally, supportive reimbursement policies, enhanced physician awareness, and continuous product launches across oncology, autoimmune diseases, and diabetes continue to strengthen North America's leadership in the global biosimilars market.

Asia Pacific is expected to register the highest growth in the biosimilars market owing to expanding biopharmaceutical manufacturing capabilities, rising demand for affordable biologic therapies, and supportive government initiatives promoting domestic biosimilar production. Countries such as India, China, South Korea, and Japan are investing significantly in biologics research, manufacturing infrastructure, and regulatory modernization to enhance market competitiveness. Growing prevalence of chronic diseases, increasing healthcare access, and rising demand for oncology, immunology, and endocrinology treatments are further driving biosimilar adoption. Moreover, the expansion of contract manufacturing organizations, strategic collaborations between regional and multinational pharmaceutical companies, and increasing approvals of biosimilar products are expected to position Asia Pacific as the fastest-growing regional market during the forecast period.

Key Trends and Drivers

Increasing Adoption of Interchangeable and Complex Biosimilars:

The Biosimilars Market is witnessing a strong trend toward the development and adoption of advanced biosimilars, including complex molecules such as monoclonal antibodies, insulin analogs, and other biologics. Pharmaceutical companies are increasingly focusing on improving biosimilar development capabilities through advanced analytical techniques, comparative clinical studies, and streamlined manufacturing processes. Regulatory approvals and growing acceptance among healthcare providers are encouraging wider adoption of biosimilars as cost-effective alternatives to expensive biologic therapies. Additionally, emerging markets are expanding access to biosimilar treatments through supportive healthcare policies and local manufacturing initiatives, further accelerating market penetration across oncology, immunology, and chronic disease applications.

Rising Demand for Cost-Effective Biologic Therapies:

The increasing need for affordable biologic treatments is a major driver of the Biosimilars Market. The high cost of originator biologics and the expiration of patents for several blockbuster biologic drugs are creating significant opportunities for biosimilar manufacturers. Healthcare systems, insurers, and governments are promoting biosimilar adoption to reduce treatment costs while maintaining therapeutic effectiveness. Growing prevalence of cancer, autoimmune disorders, diabetes, and other chronic diseases is further increasing demand for accessible biologic therapies. Moreover, advancements in biopharmaceutical manufacturing, expanding regulatory pathways, and increasing investments by pharmaceutical companies in biosimilar pipelines are supporting market growth globally.

Research Scope

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Application
• 2.4 Key Market Highlights by End User
• 2.5 Key Market Highlights by Technology
• 2.6 Key Market Highlights by Process
• 2.7 Key Market Highlights by Services
• 2.8 Key Market Highlights by Stage

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Recombinant Non-glycosylated Proteins
  • 4.1.2 Recombinant Glycosylated Proteins
  • 4.1.3 Recombinant Peptides
  • 4.1.4 Others
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Monoclonal Antibodies
  • 4.2.2 Insulin
  • 4.2.3 Erythropoietin
  • 4.2.4 Granulocyte Colony-Stimulating Factor
  • 4.2.5 Interferons
  • 4.2.6 Human Growth Hormones
  • 4.2.7 Follitropin
  • 4.2.8 Enoxaparin
  • 4.2.9 Teriparatide
  • 4.2.10 Others
• 4.3 Market Size & Forecast by Application (2020-2035)
  • 4.3.1 Oncology
  • 4.3.2 Chronic Diseases
  • 4.3.3 Autoimmune Diseases
  • 4.3.4 Blood Disorders
  • 4.3.5 Infectious Diseases
  • 4.3.6 Growth Hormone Deficiency
  • 4.3.7 Others
• 4.4 Market Size & Forecast by End User (2020-2035)
  • 4.4.1 Hospitals
  • 4.4.2 Clinics
  • 4.4.3 Research Institutes
  • 4.4.4 Biopharmaceutical Companies
  • 4.4.5 Others
• 4.5 Market Size & Forecast by Technology (2020-2035)
  • 4.5.1 Recombinant DNA Technology
  • 4.5.2 Monoclonal Antibody Technology
  • 4.5.3 Others
• 4.6 Market Size & Forecast by Process (2020-2035)
  • 4.6.1 Upstream Process
  • 4.6.2 Downstream Process
  • 4.6.3 Others
• 4.7 Market Size & Forecast by Services (2020-2035)
  • 4.7.1 Contract Research
  • 4.7.2 Contract Manufacturing
  • 4.7.3 Others
• 4.8 Market Size & Forecast by Stage (2020-2035)
  • 4.8.1 Preclinical
  • 4.8.2 Clinical
  • 4.8.3 Commercial

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Application
    • 5.2.1.4 End User
    • 5.2.1.5 Technology
    • 5.2.1.6 Process
    • 5.2.1.7 Services
    • 5.2.1.8 Stage
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Application
    • 5.2.2.4 End User
    • 5.2.2.5 Technology
    • 5.2.2.6 Process
    • 5.2.2.7 Services
    • 5.2.2.8 Stage
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Application
    • 5.2.3.4 End User
    • 5.2.3.5 Technology
    • 5.2.3.6 Process
    • 5.2.3.7 Services
    • 5.2.3.8 Stage
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Application
    • 5.3.1.4 End User
    • 5.3.1.5 Technology
    • 5.3.1.6 Process
    • 5.3.1.7 Services
    • 5.3.1.8 Stage
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Application
    • 5.3.2.4 End User
    • 5.3.2.5 Technology
    • 5.3.2.6 Process
    • 5.3.2.7 Services
    • 5.3.2.8 Stage
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Application
    • 5.3.3.4 End User
    • 5.3.3.5 Technology
    • 5.3.3.6 Process
    • 5.3.3.7 Services
    • 5.3.3.8 Stage
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Application
    • 5.4.1.4 End User
    • 5.4.1.5 Technology
    • 5.4.1.6 Process
    • 5.4.1.7 Services
    • 5.4.1.8 Stage
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Application
    • 5.4.2.4 End User
    • 5.4.2.5 Technology
    • 5.4.2.6 Process
    • 5.4.2.7 Services
    • 5.4.2.8 Stage
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Application
    • 5.4.3.4 End User
    • 5.4.3.5 Technology
    • 5.4.3.6 Process
    • 5.4.3.7 Services
    • 5.4.3.8 Stage
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Application
    • 5.4.4.4 End User
    • 5.4.4.5 Technology
    • 5.4.4.6 Process
    • 5.4.4.7 Services
    • 5.4.4.8 Stage
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Application
    • 5.4.5.4 End User
    • 5.4.5.5 Technology
    • 5.4.5.6 Process
    • 5.4.5.7 Services
    • 5.4.5.8 Stage
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Application
    • 5.4.6.4 End User
    • 5.4.6.5 Technology
    • 5.4.6.6 Process
    • 5.4.6.7 Services
    • 5.4.6.8 Stage
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Application
    • 5.4.7.4 End User
    • 5.4.7.5 Technology
    • 5.4.7.6 Process
    • 5.4.7.7 Services
    • 5.4.7.8 Stage
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Application
    • 5.5.1.4 End User
    • 5.5.1.5 Technology
    • 5.5.1.6 Process
    • 5.5.1.7 Services
    • 5.5.1.8 Stage
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Application
    • 5.5.2.4 End User
    • 5.5.2.5 Technology
    • 5.5.2.6 Process
    • 5.5.2.7 Services
    • 5.5.2.8 Stage
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Application
    • 5.5.3.4 End User
    • 5.5.3.5 Technology
    • 5.5.3.6 Process
    • 5.5.3.7 Services
    • 5.5.3.8 Stage
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Application
    • 5.5.4.4 End User
    • 5.5.4.5 Technology
    • 5.5.4.6 Process
    • 5.5.4.7 Services
    • 5.5.4.8 Stage
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Application
    • 5.5.5.4 End User
    • 5.5.5.5 Technology
    • 5.5.5.6 Process
    • 5.5.5.7 Services
    • 5.5.5.8 Stage
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Application
    • 5.5.6.4 End User
    • 5.5.6.5 Technology
    • 5.5.6.6 Process
    • 5.5.6.7 Services
    • 5.5.6.8 Stage
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Application
    • 5.6.1.4 End User
    • 5.6.1.5 Technology
    • 5.6.1.6 Process
    • 5.6.1.7 Services
    • 5.6.1.8 Stage
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Application
    • 5.6.2.4 End User
    • 5.6.2.5 Technology
    • 5.6.2.6 Process
    • 5.6.2.7 Services
    • 5.6.2.8 Stage
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Application
    • 5.6.3.4 End User
    • 5.6.3.5 Technology
    • 5.6.3.6 Process
    • 5.6.3.7 Services
    • 5.6.3.8 Stage
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Application
    • 5.6.4.4 End User
    • 5.6.4.5 Technology
    • 5.6.4.6 Process
    • 5.6.4.7 Services
    • 5.6.4.8 Stage
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Application
    • 5.6.5.4 End User
    • 5.6.5.5 Technology
    • 5.6.5.6 Process
    • 5.6.5.7 Services
    • 5.6.5.8 Stage

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Amgen
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Novartis
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Pfizer
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 Samsung Bioepis
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 Celltrion
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Biocon
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 Sandoz
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Mylan
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 Teva Pharmaceuticals
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Fresenius Kabi
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Dr Reddys Laboratories
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Hoffmann La Roche
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Lupin Limited
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 STADA Arzneimittel
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Coherus BioSciences
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 Boehringer Ingelheim
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Apotex
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 Zydus Cadila
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Alvotech
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Torrent Pharmaceuticals
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us